Source: Lieyun Network
Recently, Shenzhen Raysightmed Co., Ltd. (hereinafter referred to as “RaysightMed”) completed a new round of strategic financing amounting to nearly RMB 100 million, jointly invested by Haihe Industrial Fund and Zhongli Fund, representing state-owned industrial capital at both municipal and district levels.
It is reported that this round of financing will focus on advancing the commercial promotion and capacity upgrade of the full product line, prioritizing efforts in coronary physiology, non-invasive coronary assessment, and intracardiac echocardiography (ICE) product lines, to continuously expand the clinical penetration rate and market share of domestically produced innovative cardiovascular devices.
RaysightMed is an innovative medical enterprise that began its product development with CT-FFR (non-invasive fractional flow reserve) and has since advanced into AI-driven intelligent solutions and precision diagnosis and treatment for cardiovascular and cerebrovascular diseases.
Leveraging this round of financing, the Company will deepen its footprint in the real economy in Tianjin by establishing standardized production facilities and building a mass-production system for high-end medical devices. Through a dual strategy of manufacturing bases coupled with regional marketing centers, the Company will comprehensively cover the core healthcare markets in North, Northeast, and Northwest China, thereby completing its national industrialization and distribution network. This will provide robust capacity and service support to rapidly scale up sales of its currently approved products.
Zheng Lingxiao, Founder and CEO of RaysightMed, stated that the capital injection from Tianjin state-owned assets and the establishment of local industrial operations will provide ample funding and industrial support for the company’s R&D of advanced AI-powered surgical robots and the promotion of its chronic disease health management products. The company will continue to root itself in local clinical needs, refine its portfolio of products for cerebrovascular and cardiovascular diseases, steadily advance product commercialization, and accelerate its growth into a globally competitive leader in intelligent cardiovascular healthcare.